Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Neo Soma Healthcare vs Spry

Neo Soma Healthcare
Graded #213

Higher grade

vs+9
Spry
Graded #408

Lower grade

The verdict

Neo Soma Healthcare takes it — 65.8/100 to 56.8/100.

Neo Soma Healthcare grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Neo Soma Healthcare is a multi-product DTC telehealth platform pairing compounded GLP-1 weight management with sexual-health and anti-aging lines.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNeo Soma Healthcare +12
66
54
Dose & formulationNeo Soma Healthcare +8
72
64
Clinical oversightNeo Soma Healthcare +17
72
55
Labs & monitoringNeo Soma Healthcare +10
62
52
FulfillmentSpry +4
57
61
Contract termsEven
55
55
Neo Soma Healthcare · left barSpry · right bar

The numbers

MetricNeo Soma HealthcareSpry
WeighScore65.8/10056.8/100
GradeCC
Scorecard rank#213#408
Semaglutide$199/mo$199/mo (starting dose, compounded)
Tirzepatide$330/mo$299/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Neo Soma Healthcare

Graded #213 · C

Strengths

  • LegitScript verification badge present
  • Publishes the FDA compounded-medication disclaimer
  • Pricing shown publicly for all 6 product lines
  • Multi-product platform (GLP-1, sexual health, peptide therapies)
  • First-month discount on semaglutide ($99 entry)

Where it loses points

  • Pharmacy partner not named (503A vs 503B unclear)
  • States served not listed — no per-state availability table
  • No named medical director
  • Standard semaglutide pricing ($199/mo) above the cheapest providers ($150–180/mo)
  • Tirzepatide entry pricing ($330) above the cheapest providers (~$200–250/mo)
Spry

Graded #408 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard